Literature DB >> 32495848

Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents.

A Izzi1, V Messina, L Rinaldi, P Maggi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32495848     DOI: 10.26355/eurrev_202005_21297

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


× No keyword cloud information.
  5 in total

1.  Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

Authors:  Onat Kadioglu; Mohamed Saeed; Henry Johannes Greten; Thomas Efferth
Journal:  Comput Biol Med       Date:  2021-03-30       Impact factor: 6.698

2.  Re-purposing of hepatitis C virus FDA approved direct acting antivirals as potential SARS-CoV-2 protease inhibitors.

Authors:  Reaz Uddin; Khurshid Jalal; Kanwal Khan; Zaheer Ul-Haq
Journal:  J Mol Struct       Date:  2021-11-19       Impact factor: 3.196

3.  Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19.

Authors:  Vincenzo Messina; Riccardo Nevola; Antonio Izzi; Pellegrino De Lucia Sposito; Aldo Marrone; Roberto Rega; Raffaele Fusco; Paolina Lumino; Luca Rinaldi; Pasqualina Gaglione; Filomena Simeone; Ferdinando Carlo Sasso; Paolo Maggi; Luigi Elio Adinolfi
Journal:  Sci Rep       Date:  2022-04-06       Impact factor: 4.379

4.  Promising Therapeutic Approach for SARS-CoV-2 Infections by Using a Rutin-Based Combination Therapy.

Authors:  Monika Mazik
Journal:  ChemMedChem       Date:  2022-05-24       Impact factor: 3.540

5.  Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.

Authors:  Steffen Jockusch; Chuanjuan Tao; Xiaoxu Li; Minchen Chien; Shiv Kumar; Irina Morozova; Sergey Kalachikov; James J Russo; Jingyue Ju
Journal:  Sci Rep       Date:  2020-10-06       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.